STADA Arzneimittel : to acquire Walmark – a leading Consumer Healthcare company in Central Europe

• Walmark is a manufacturer of well-established, market-leading Consumer Health brands in Central Europe
• Strong growth potential in existing Walmark geographies and across Europe, supported by STADA's investment in the further commercialisation of Walmark's products
• STADA CEO Peter Goldschmidt: 'With the acquisition of Walmark, we are able to broaden our portfolio of branded Consumer Health products in Central Europe and further internationalise our overall business.'

Bad Vilbel, November 4, 2019 - STADA Arzneimittel AG ('STADA' or 'the Group') today announces the acquisition of Walmark a.s. ('Walmark' or 'the company') from Mid Europa Partners for an undisclosed consideration.

Walmark is a leading manufacturer of Consumer Health products in Central Europe with a unique portfolio of well-established Consumer Health brands across multiple categories. These include Vitamins and Minerals, Children's Health, Women's Health, Men's Health, Joint Care, Digestive and Intestinal, and Cough and Cold and are set to generate continued strong growth. Its key brands include e.g. Biopron (gut health), Martians (children's supplements), Urinal (urinary tract health), Proenzi (joint care), Prostenal (male health), Beliema (vaginal health) and Sinulan (respiratory health).

Established in 1990 and headquartered in the Czech Republic, Walmark has a direct presence across nine European Union countries, including the Czech Republic, Slovakia, Poland, Hungary, Bulgaria, Romania, Lithuania, Latvia and Estonia, and sells its products to more than 40 countries worldwide. It employs more than 540 people and has a strong focus on innovation. STADA will integrate Walmark's high quality manufacturing facility in Trinec into STADA's global production network.

'With Walmark, we are further strengthening STADA's global branded products portfolio', stated STADA CEO Peter Goldschmidt. 'The acquisition of Walmark's OTC portfolio is fully aligned with our strategy of being a leader in branded consumer health products and generics.'

STADA operates in diversified markets with robust growth prospects. The Group is pursuing a two-pillar strategy focused on generics, including specialty pharmaceuticals, and non-prescription consumer health products. Walmark's product portfolio is highly complementary to STADA's existing portfolio.

Steffen Wagner, Head of European Markets at STADA, comments:
'We are significantly strengthening our presence in Central Europe - especially in the Czech Republic, Slovakia, Romania, Bulgaria, and Hungary - as a result of this acquisition. We are also looking at ways in which we can market the Walmark brands outside of the current core geographies.'

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The Group is pursuing a two pillar strategy focused on generics, including specialty pharmaceuticals, and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany / Phone: [phone] / Fax: [phone] / E-Mail: [e-mail]

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany / Phone: [phone] / Fax: [phone] / E-mail: [e-mail]

Or visit us on the Internet at www.stada.com/investor-relations